Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCAB
stocks logo

BCAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.220
-26.67%
--
--
-0.200
-23.08%
--
--
-0.170
-46.88%
Estimates Revision
The market is revising No Change the revenue expectations for BioAtla, Inc. (BCAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 58.06%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.75%
In Past 3 Month
Stock Price
Go Up
up Image
+58.06%
In Past 3 Month
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 0.848
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 0.848
sliders
Low
10.00
Averages
10.00
High
10.00
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
$NULL
2025-08-13
Reason
Citizens JMP
Reni Benjamin
Price Target
$NULL
2025-08-13
downgrade
Outperform -> Market Perform
Reason
Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.
HC Wainwright & Co.
Arthur He
Hold
Reiterates
n/a
2025-03-31
Reason
HC Wainwright & Co.
Arthur He
Price Target
n/a
2025-03-31
Reiterates
Hold
Reason
Citizens Capital Markets
Reni Benjamin
Buy
Maintains
$5 → $1
2025-03-31
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$5 → $1
2025-03-31
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bioatla Inc (BCAB.O) is -0.88, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess Bioatla Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.32
Current PE
-0.88
Overvalued PE
2.25
Undervalued PE
-10.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.80
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.19
Undervalued EV/EBITDA
-8.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
76.34
Current PS
0.00
Overvalued PS
186.41
Undervalued PS
-33.72
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 760.39% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BCAB News & Events

Events Timeline

(ET)
2025-11-13
16:17:24
BioAtla Announces Q3 Earnings Per Share of 27 Cents, Below Consensus Estimate of 30 Cents
select
2025-11-07 (ET)
2025-11-07
09:09:07
BioAtla Reveals Findings on Mecbotamab Vedotin
select
2025-10-20 (ET)
2025-10-20
08:10:04
BioAtla Reveals Initial Findings from Phase 1 Trial of BA3182
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

  • BioAtla Inc. Gains: BioAtla's shares surged 13.94% in after-hours trading, attributed to investor reactions to recent financing agreements, despite no new company-specific news.

  • Metagenomi Inc. and PAVmed Inc. Movements: Metagenomi's stock rose 5.71% with no new updates, while PAVmed advanced 5.72% after reporting a significant net loss and a sharp decline in revenue.

  • Precision BioSciences' Positive Outlook: Precision BioSciences gained 2.94% after announcing it will present Phase 1 trial data at an upcoming conference, boosting investor optimism.

  • Entero Therapeutics Rebranding: Entero Therapeutics' shares increased 3.68% following its announcement of a rebranding to GridAI Technologies Corp., effective December 1, 2025, along with a new ticker symbol.

[object Object]
Preview
8.5
11-21Newsfilter
BioAtla Secures Flexible Financing Agreements Worth Up to $22.5 Million

  • Financial Agreements: BioAtla has entered into Pre-paid Advance Agreements and a Standby Equity Purchase Agreement, providing a total of $7.5 million in advance and a potential $15 million in common stock purchases to support its operations while finalizing a strategic partnership.

  • Strategic Partnership: The company is in advanced stages of completing a strategic transaction with a potential partner, aiming to finalize the deal by the end of the year, which is expected to unlock significant value for BioAtla and its shareholders.

  • Operational Momentum: These financial agreements are intended to maintain BioAtla's operational momentum during the partnership finalization process, ensuring continued progress in its clinical-stage biotechnology initiatives.

  • Product Development: BioAtla is focused on developing its CAB platform technology, which includes novel antibody therapeutics for treating solid tumors, with ongoing clinical studies for products like ozuriftamab vedotin and BA3182 targeting advanced adenocarcinoma.

[object Object]
Preview
4.5
11-14TipRanks
VTI ETF Daily Update - November 14, 2025

  • VTI ETF Performance: The Vanguard Total Stock Market ETF (VTI) is down 0.47% over the past five days but has gained 17% year-to-date. It experienced a decline of 1.77% on Thursday, mirroring broader market trends with the Nasdaq and S&P 500 also falling.

  • Technical Indicators: VTI is currently trading at $329.91, above its 50-day moving average of $327.90, indicating a bullish trend. It has a Strong Buy rating from TipRanks based on technical analysis.

  • Investor Activity: VTI saw a net inflow of $419 million over the past five trading days, with a three-month average trading volume of 4.02 million shares, suggesting continued investor interest.

  • Top Holdings and Potential: VTI's top holdings include Nvidia, Microsoft, and Apple. The ETF has a Moderate Buy rating with an average price target of $396.26, indicating a potential upside of 20.11%.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bioatla Inc (BCAB) stock price today?

The current price of BCAB is 0.848 USD — it has increased 2.66 % in the last trading day.

arrow icon

What is Bioatla Inc (BCAB)'s business?

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

arrow icon

What is the price predicton of BCAB Stock?

Wall Street analysts forecast BCAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAB is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bioatla Inc (BCAB)'s revenue for the last quarter?

Bioatla Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Bioatla Inc (BCAB)'s earnings per share (EPS) for the last quarter?

Bioatla Inc. EPS for the last quarter amounts to -0.27 USD, increased 22.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bioatla Inc (BCAB)'s fundamentals?

The market is revising No Change the revenue expectations for BioAtla, Inc. (BCAB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 58.06%.
arrow icon

How many employees does Bioatla Inc (BCAB). have?

Bioatla Inc (BCAB) has 61 emplpoyees as of December 05 2025.

arrow icon

What is Bioatla Inc (BCAB) market cap?

Today BCAB has the market capitalization of 49.83M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free